Three decades of messenger RNA vaccine development

Publication date: Available online 23 August 2019Source: Nano TodayAuthor(s): Rein Verbeke, Ine Lentacker, Stefaan C. De Smedt, Heleen DewitteAbstractIn the early nineties, pioneering steps were taken in the use of mRNA as a therapeutic tool for vaccination. In the following decades, an improved understanding of the mRNA pharmacology, together with novel insights in immunology have positioned mRNA-based technologies as next-generation vaccines. This review outlines the history and current state-of-the-art in mRNA vaccination, while presenting an immunological view on mRNA vaccine development. As such, we highlight the challenges in vaccine design, testing and administration, key considerations in the design of mRNA-based vaccines and new opportunities that arise when packaging mRNA in nanoparticulate vaccines. Finally, we discuss the mRNA self-adjuvant effect as a critical, but dichotomous parameter that determines the safety, efficacy and strength of the evoked immune response.Graphical abstract
Source: Nano Today - Category: Nanotechnology Source Type: research

Related Links:

Emergency-use authorizations, a formerly obscure corner of regulatory law, have become a centerpiece of the government ’s response to the pandemic.
Source: NYT - Category: American Health Authors: Tags: your-feed-science Coronavirus Risks and Safety Concerns Food and Drug Administration Hahn, Stephen M (1960- ) Coronavirus (2019-nCoV) Vaccination and Immunization Clinical Trials Drugs (Pharmaceuticals) your-feed-health your-feed-healthc Source Type: news
The use of an immune-system stimulant harvested from shark liver oil in the development of some coronavirus vaccines has animal conservationists pressing for alternatives.(Image credit: Reinhard Dirscherl/ullstein bild via Getty Images)
Source: NPR Health and Science - Category: Consumer Health News Authors: Source Type: news
Authors: Abdeta D, Kebede N, Giday M, Terefe G, Abay SM Abstract Microbial resistance to the few conventional antitrypanosomal drugs, increasing resistance of vectors to insecticides, lack of effective vaccines, and adverse effects of the existing antitrypanosomal drugs justify the urgent need for effective, tolerable, and affordable drugs. We assessed antitrypanosomal effects of the hydromethanolic extract of Echinops kebericho Mesfin roots against Trypanosoma congolense field isolate using in vitro and in vivo techniques. Parasite load, packed cell volume (PCV), body weight, and rectal temperature in Swiss albino...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Phoenix Children ’s Hospital held its fourth annual flu POD (point of distribution) this week, with this year's 13-hour blitz holding a special significance amid the global Covid-19 pandemic. On Oct. 7, nurses began vaccinating employees at 6 a.m. and concluded the one-day event at 7 p.m., vaccinating nearly 5,00 0 people. It’s preparation for another potential mass vaccination event: distribution of a safe and effective vaccine for Covid-19. Click through the photo gallery above to see scenes…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
In this study, we modeled an alternative strategy to amplify tumor antigen-specific TCR transgenic CD8+ T cells through limited application of a long-acting IL-2 fusion protein, mIL-2/mCD25, which selectively targets the high-affinity IL-2R. Here, mice were vaccinated with a tumor antigen and high-dose mIL-2/mCD25 was applied to coincide with the induction of the high affinity IL-2R on tumor-specific T cells. A single high dose of mIL-2/mCD25, but not an equivalent amount of IL-2, amplified the frequency and function of tumor-reactive CD8+ T effector (Teff) and memory cells. These mIL-2/mCD25-dependent effects relied on di...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
According to officials, the Hyderabad-based vaccine maker applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
DiscussionThe results of this realist review will be written up according to RAMESES guidelines and disseminated through a stakeholder workshop in Malawi, through conference presentations and peer-reviewed publications. It is intended to improve the understanding of the potential and limits of working through Care Groups globally and among relevant Malawi Ministry of Health staff and the donor and NGO community, both internationally and within Malawi. This systematic review protocol has been submitted for registration on the PROSPERO database (receipt number: 170261).
Source: Systematic Reviews - Category: International Medicine & Public Health Source Type: research
ConclusionsPatients on various solid tumour treatments achieve sero-protection rate congruent with the general population. The sero-protection HIA titres were not sustained at 24  weeks postvaccination.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p0").init({"mcp":"cbs","width":"100%","height":"100%","video":"4778215","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p0","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Covid-19 Boston, MA Health Healthwatch Seen On WBZ-TV Syndicated Local Coronavirus Dr. Mallika Marshall Source Type: news
A Trump administration official leading the response to the coronavirus pandemic says the U.S. can expect delivery of a vaccine starting in January 2021, despite statements from the president that inoculations could begin this month
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
More News: Allergy & Immunology | Drugs & Pharmacology | Nanotechnology | Vaccines